Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, ritlecitinib, an oral JAK3/TEC inhibitor, was evaluated for safety in patients aged 12 and older with alopecia areata across four clinical trials up to 36 months, showing a safety profile with reported adverse events and lab abnormalities summarized per dosing groups.

This review reports that innovative topical treatments for dermatologic conditions like acne and atopic dermatitis show minimal systemic absorption, indicating improved safety and tolerability compared to traditional therapies.

This study evaluated a new nanogel formulation containing Ciclopirox Olamine for treating cutaneous candidiasis, finding that the optimized version offered improved skin penetration, sustained drug release, and effective antifungal action against Candida albicans compared to conventional treatment.

This case report describes successful treatment of anaplasmosis in a Kintamani mix dog with doxycycline, ivermectin, vetadryl, and Livron b-plex, leading to improved activity, hair growth, appetite, and tick eradication.

This study found that switching patients with glaucoma or ocular hypertension from benzalkonium chloride-latanoprost to preservative-free latanoprost maintained intraocular pressure control and improved tolerability, potentially enhancing treatment adherence and quality of life.

This case report describes the successful treatment of a 13-year-old girl's autoimmune symptoms with co-trimoxazole, an antibiotic with immunomodulatory properties.

This systematic review and meta-analysis reported that deuruxolitinib is effective for hair regrowth and improving patient-reported outcomes in individuals with moderate to severe alopecia areata, but observed manageable treatment-emergent adverse events such as elevated creatinine kinase levels and headaches, particularly with higher doses.

This study found that econazole nitrate delivered via MPEG-dihexPLA micelles significantly increased skin deposition compared to Pevaryl® cream, potentially enhancing drug bioavailability and clinical efficacy.

In this case study, a 13-year-old girl with multiple autoimmune symptoms was successfully treated with the antibiotic and immunomodulatory drug co-trimoxazole.

This study found that ritlecitinib 50 mg is cost-effective compared to no treatment for patients in Japan with alopecia areata and significant scalp hair loss, demonstrating an incremental cost-effectiveness ratio below the country's cost-effectiveness threshold.

In this study, phage-containing hydrogels were shown to effectively treat wounds infected with E. faecalis by promoting wound healing through controlled phage release, suggesting potential to improve clinical outcomes for such infections.

This open-access journal publishes innovative research articles across various fields but reports no new clinical results in this summary.

This study developed two types of polymeric nanoparticles containing clindamycin phosphate for potential topical acne treatment and found that the NP-AH-CDM-4 formulation preferentially penetrated hair follicles even with sebaceous obstruction, suggesting its promise for more effective acne therapy without causing skin irritation.

In this randomized controlled trial, researchers observed that topical clobetasol propionate 0.05% was significantly more effective than topical tacrolimus 0.1% for treating alopecia areata, with a higher treatment success rate of 74.2% versus 45.2%, suggesting clobetasol as a preferred first-line topical therapy.

This study suggests that nanostructured lipid carriers loaded with spironolactone might improve localized delivery to hair follicles for treating androgenic alopecia, potentially minimizing systemic side effects.

In this study, daily treatment with angiotensin (1-7) significantly reduced disease severity in a mouse model of Systemic Lupus Erythematosus, suggesting potential for Mas agonists in future therapies.

This review discusses the potential benefits of nonantibiotic macrolides for treating inflammatory skin disorders and reports no new clinical results.

This study examined the safety profile of ritlecitinib, a drug for alopecia areata, and found that it does not cause significant QTc prolongation or severe lymphopenia, with no unique safety risks expected in adolescents.

This study found that both fluoxetine and clomipramine are effective in treating psychogenic triggers of acral lick dermatitis in dogs, with fluoxetine leading to quicker recovery and lower recurrence rates, while clomipramine showed better overall recovery rates but was associated with fewer side effects.

This study found that combined therapy with cetirizine and topical steroids stabilized inflammation in most patients with lichen planus pilaris, though one patient experienced cardiac arrhythmia.

The trial helped find the best dose of deuruxolitinib for treating alopecia areata.

This study identified new and recurrent missense mutations in the PHGDH and PSAT1 genes, implicating them in the pathogenesis of Neu-Laxova syndrome in Chinese patients.

In this randomized controlled trial, both Botulinum Toxin-A and Triamcinolone Acetonide showed substantial effectiveness in treating patchy Alopecia Areata, but Botulinum Toxin-A avoided complications while Triamcinolone led to skin atrophy in 16.7% of patients.

In this study on tolerant rats, maternal and developmental toxicity from levo-alpha-acetyhnethadol hydrochloride were observed at all doses, without specific fetal toxicity or teratogenic effects.

In this study, spironolactone was found to be a safe and effective treatment for acne in women over 25 with abnormal hormone levels, while younger women with normal hormone levels showed less response.

The researchers reported that zinc carbonate nanoparticles stabilized with polyvinylpyrrolidone did not show local irritant or skin-resorptive effects in preclinical tests on rabbits and rats.

This study concluded that adding Kanglaite injection to gemcitabine and cisplatin chemotherapy for advanced non-small cell lung cancer improved response rates and reduced adverse side effects.

Renal transplant patients on tacrolimus and sirolimus may develop acne keloidalis nuchae.